Oops, that page doesn't exist!

The European Medicines Agency’s human medicines committee is meeting this week due to decide whether or not to back pan-EU marketing approval for a number of new drugs.

Companies are being encouraged to look at whether they will be impacted by new UK rules on supplementary protection certificates that come into effect from the beginning of next year.

Finland is the latest market launch for OTC erectile dysfunction treatment Eroxon. High demand for the product in other countries, such as Norway, helped drive up Navamedic's consumer health sales in the first nine months of 2024.

The UK-based major is set for near double-digit growth in 2024 but has become mired in concerns over a fraud probe in China on its third quarter call.

Pimicotinib’s Phase III data in tenosynovial giant cell tumor are better than its rivals but the fight for a small number of patients will be fierce.